The selective polo-like kinase (Plk1) inhibitor onvansertib and the antiandrogen abiraterone synergistically kill cancer cells through disruption of mitosis independently of androgen receptor signaling.-MedSci.cn

The selective polo-like kinase (Plk1) inhibitor onvansertib and the antiandrogen abiraterone synergistically kill cancer cells through disruption of mitosis independently of androgen receptor signaling.

Patterson, JC; Croucher, PJ; Ridinger, M; Einstein, DJ; Varkaris, A; Balk, SP; Bubley, GJ; Erlander, MG; Yaffe, MB

CANCER RESEARCH, 2021; 81 (13):

科室
- - 订阅+
  - 更多科室
工具
服务